We offer a specialized service based on a unique human whole-blood loop assay, for detection of acute immune-related side effects of biopharmaceuticals (cytokine release), which provides a better understanding of first-in-man reactions prior to clinical trial entry. The assay platform can also be used to perform mode-of-action studies.
We are developing a new generation therapeutic peptide-based immuno-oncology vaccine powered by proprietary and patent-protected advanced TET technology that will enhance both peptide uptake and cellular immune activation. Our strategy is based on the delivery of our vaccine in an antigen-antibody immune complex formula. The primary focus is early stage, high-risk prostate cancer but the platform can be used for developing vaccines for other indications.
Are you interested in using our whole-blood loop model to assess toxicity or/and efficacy of your drug candidate? Contact us to find out how we can help you!
Are you interested in our patented TET-platform for development of cancer vaccines? Or would like to invest in the current project in the pipeline? Sign up to receive our latest news on drug development or investors’ information!
Meet us at Nordic Life Science Days in Malmö September 12-14. During the conference, Justyna Leja-Jarblad, Laboratory Manager will give a pitch about our Immuno-Oncology project, at the Start Up Challenge on September 12 at 18:30. We are open to partnering meetings throughout the conference. Come and talk to us about our Immuno-Service, Immuno-Oncology, potential collaboration, or anything that interests you!
Immuneed has secured SEK 9M in an oversubscribed financing round. The funding will support the pre-clinical work of our Immuno-Oncology cancer vaccine and be used to increase marketing of the companys analysis service. The new funding secures financing of our pre-clinical program for the cancer vaccine and further engagement for contract manufacturing.
Because we're up to something good...